March 28, 2013
…host insightful talks on subjects, including stress reduction, gene therapy for heart repair, cancer prevention, successfully reducing menopause symptoms, and achieving longevity through diet and fitness.
May 26, 2015
The Huntington’s Disease Clinical Research Center (HDCRC) at UC San Diego Health System has been designated a Center of Excellence by the Huntington’s Disease Society of America (HDSA). UC San Diego was one of only 29 centers nationwide to receive this prestigious designation, which recognizes centers for their elite multidisciplinary…
January 8, 2019
FDA approves first U.S. clinical trial of an intravenously administered bacteriophage-based therapy to treat resistant bacterial infections.
February 2, 2017
…for children with KD who are resistant to initial therapy.
November 30, 2018
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
April 22, 2019
University of California San Diego School of Medicine researchers found that treating patients with personalized precision medicine that combined therapies to target multiple alterations improved outcomes in patients with therapy resistant cancers.
May 30, 2017
…provides both parents and children with education and behavior therapy techniques but is provided mainly in a hospital setting. Researchers at University of California San Diego School of Medicine have found that parent-based therapy (PBT) has similar outcomes to FBT and could be more cost-effective.
July 8, 2021
Treatment provides non-opiate alternative that is minimally invasive with emphasis on functional restoration.
April 1, 2019
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
November 14, 2011
…determination of the optimum physical and chemical conditions that direct the differentiation of stem cells into specific cell types. The ability to control stem cell differentiation to desired cell types is crucial for the use of human embryonic stem cells for regenerative medicine, and hence the results of this study…
